Organogenesis Holdings Aktie News

Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Ross Osborn - Cantor Fitzgerald Drew Ranieri - Morgan Stanley Operator Welcome ladies and gentlemen to the First Quarter an...

CANTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that its Phase 3 randomized control trial evaluating the safety and efficacy of ReNu, a cryopre...

CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2024 financial results will be reported after the market clos...

CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York gr...

To put it charitably, the market wasn't impressed with the company's recent performance. They traded out of the stock following the publication of quarterly and annual results.

Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript

CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2023.

CANTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the BTIG Snowbird MedTech, Digital Health, Life Science and ...